Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $30.8 million.

  • Arrowhead Pharmaceuticals' Profit After Tax rose 11758.44% to $30.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $230.6 million, marking a year-over-year increase of 13550.22%. This contributed to the annual value of $30.1 million for FY2025, which is 10493.92% up from last year.
  • Arrowhead Pharmaceuticals' Profit After Tax amounted to $30.8 million in Q4 2025, which was up 11758.44% from $8.0 million recorded in Q3 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Profit After Tax peaked at $370.4 million during Q1 2025, and registered a low of -$178.7 million during Q2 2025.
  • Moreover, its 5-year median value for Profit After Tax was -$67.7 million (2021), whereas its average is -$53.0 million.
  • In the last 5 years, Arrowhead Pharmaceuticals' Profit After Tax crashed by 36090.6% in 2024 and then skyrocketed by 39169.82% in 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Profit After Tax (Quarter) stood at -$62.9 million in 2021, then soared by 33.5% to -$41.8 million in 2022, then crashed by 223.78% to -$135.4 million in 2023, then fell by 29.43% to -$175.2 million in 2024, then soared by 117.58% to $30.8 million in 2025.
  • Its Profit After Tax stands at $30.8 million for Q4 2025, versus $8.0 million for Q3 2025 and -$178.7 million for Q2 2025.